Maravai LifeSciences
MRVI
202 hedge funds and large institutions have $3.34B invested in Maravai LifeSciences in 2022 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 71 increasing their positions, 73 reducing their positions, and 46 closing their positions.
530% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $1.73M
0.32% less ownership
Funds ownership: 99.72% → 99.4% (-0.32%)
3% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 73
6% less funds holding
Funds holding: 216 → 202 (-14)
10% less capital invested
Capital invested by funds: $3.72B → $3.34B (-$383M)
28% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 46
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$64.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$42.4M |
| 3 |
Millennium Management
New York
|
+$42.3M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$38.6M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$37.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$68.8M |
| 2 |
Select Equity Group
New York
|
-$66.8M |
| 3 |
Morgan Stanley
New York
|
-$38.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$37.1M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$30.8M |
MRVI Hedge Fund Activity: Q3 2022 in Review
202 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q3 2022, worth a combined $3.34B — down 10% from $3.72B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of MRVI and 33 opened new positions — a net loss of 13 holders — while 73 trimmed existing stakes and 71 added.
The largest buyer was Thrivent Financial for Lutherans, opening a new position worth an estimated $64.2M. The largest seller was Champlain Investment Partners, exiting entirely with an estimated $68.8M sold.
- 202 institutional investors held Maravai LifeSciences (MRVI) as of Q3 2022, down from 216 in Q2 2022.
- Funds reported $3.34B of Maravai LifeSciences stock for Q3 2022, down 10% quarter-over-quarter.
- 33 funds opened new Maravai LifeSciences positions in Q3 2022 and 46 closed out, a net change of -13 holders.
- The largest Maravai LifeSciences buyer in Q3 2022 was Thrivent Financial for Lutherans, an estimated $64.2M added.
- The largest Maravai LifeSciences seller in Q3 2022 was Champlain Investment Partners, an estimated $68.8M sold.
Based on aggregated 13F filings for Q3 2022.